WEKO3
アイテム
{"_buckets": {"deposit": "d0fc844e-ce30-4f44-98d2-16d011ee5031"}, "_deposit": {"created_by": 2, "id": "9181", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "9181"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00009181", "sets": ["9"]}, "author_link": ["36707", "36711", "36706", "36710", "36703", "36708", "36704", "36712", "36709", "36713", "36705"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-06-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "1745", "bibliographicPageStart": "1737", "bibliographicVolumeNumber": "23", "bibliographic_titles": [{"bibliographic_title": "Osteoporosis International"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Summary Monthly minodronate at 30 or 50 mg had similar efficacy as 1 mg daily in terms of change in bone mineral density (BMD) and bone turnover markers with similar safety profiles. This new regimen provides patients with a new option for taking minodronate. Introduction Minodronate at a daily oral dose of 1 mg has been proven to have antivertebral fracture efficacy. In the present study, the efficacy and safety of oral minodronate at monthly doses of either 30 mg or 50 mg were compared with a daily dose of 1 mg. Methods A total of 692 patients with involutional osteoporosis were randomized to receive minodronate at either 30 or 50 mg monthly or a daily dose of 1 mg. The primary endpoint was the percent change from baseline in lumbar spine (LS) BMD at 12 months. Total hip BMD, bone turnover markers, serum calcium (Ca), and parathyroid hormone (PTH) levels were also evaluated. Results Minodronate at monthly doses of 30 or 50 mg were noninferior to the 1 mg daily dose in terms of change in LS-BMD. Changes in total hip BMD were also comparable. Although a transient decrease in serum Ca and increase in PTH levels were observed in all three groups at slightly different magnitudes and time courses, changes in bone turnover markers were comparable among the differentdosage groups with a similar time course. Safety profiles were also comparable. Conclusion Minodronate at monthly doses of 30 or 50 mg has similar efficacy to the daily 1 mg dose in terms of BMD and bone turnover markers with similar tolerability.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Osteoporosis International, 23(6), pp.1737-1745; 2012", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer-Verlag"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s00198-011-1782-z", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© The Author(s) 2011. This article is published with open access at Springerlink.com"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0937941X", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14332965", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Okazaki, Ryo"}], "nameIdentifiers": [{"nameIdentifier": "36703", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hagino, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "36704", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Masako"}], "nameIdentifiers": [{"nameIdentifier": "36705", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sone, Teruki"}], "nameIdentifiers": [{"nameIdentifier": "36706", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Toshitaka"}], "nameIdentifiers": [{"nameIdentifier": "36707", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizunuma, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "36708", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukunaga, Masao"}], "nameIdentifiers": [{"nameIdentifier": "36709", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shiraki, Masataka"}], "nameIdentifiers": [{"nameIdentifier": "36710", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishizawa, Yoshiki"}], "nameIdentifiers": [{"nameIdentifier": "36711", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohashi, Yasuo"}], "nameIdentifiers": [{"nameIdentifier": "36712", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto, Toshio"}], "nameIdentifiers": [{"nameIdentifier": "36713", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "OI23_1737.pdf", "filesize": [{"value": "590.6 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 590600.0, "url": {"label": "OI23_1737.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/9181/files/OI23_1737.pdf"}, "version_id": "d413ffbb-52c7-4282-94ea-edaa3f365ef1"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Bone mineral density", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Bone turnover marker", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Minodronate", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Monthly bisphosphonate", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Osteoporosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "PTH", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis"}]}, "item_type_id": "2", "owner": "2", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/29766", "pubdate": {"attribute_name": "公開日", "attribute_value": "2012-11-16"}, "publish_date": "2012-11-16", "publish_status": "0", "recid": "9181", "relation": {}, "relation_version_is_last": true, "title": ["Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis"], "weko_shared_id": -1}
Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
http://hdl.handle.net/10069/29766
http://hdl.handle.net/10069/29766a6ffe069-0f4b-451f-a6bc-6cd6a448cd9c
名前 / ファイル | ライセンス | アクション |
---|---|---|
OI23_1737.pdf (590.6 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2012-11-16 | |||||
タイトル | ||||||
タイトル | Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Bone mineral density | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Bone turnover marker | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Minodronate | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Monthly bisphosphonate | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Osteoporosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | PTH | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Okazaki, Ryo
× Okazaki, Ryo× Hagino, Hiroshi× Ito, Masako× Sone, Teruki× Nakamura, Toshitaka× Mizunuma, Hideki× Fukunaga, Masao× Shiraki, Masataka× Nishizawa, Yoshiki× Ohashi, Yasuo× Matsumoto, Toshio |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Summary Monthly minodronate at 30 or 50 mg had similar efficacy as 1 mg daily in terms of change in bone mineral density (BMD) and bone turnover markers with similar safety profiles. This new regimen provides patients with a new option for taking minodronate. Introduction Minodronate at a daily oral dose of 1 mg has been proven to have antivertebral fracture efficacy. In the present study, the efficacy and safety of oral minodronate at monthly doses of either 30 mg or 50 mg were compared with a daily dose of 1 mg. Methods A total of 692 patients with involutional osteoporosis were randomized to receive minodronate at either 30 or 50 mg monthly or a daily dose of 1 mg. The primary endpoint was the percent change from baseline in lumbar spine (LS) BMD at 12 months. Total hip BMD, bone turnover markers, serum calcium (Ca), and parathyroid hormone (PTH) levels were also evaluated. Results Minodronate at monthly doses of 30 or 50 mg were noninferior to the 1 mg daily dose in terms of change in LS-BMD. Changes in total hip BMD were also comparable. Although a transient decrease in serum Ca and increase in PTH levels were observed in all three groups at slightly different magnitudes and time courses, changes in bone turnover markers were comparable among the differentdosage groups with a similar time course. Safety profiles were also comparable. Conclusion Minodronate at monthly doses of 30 or 50 mg has similar efficacy to the daily 1 mg dose in terms of BMD and bone turnover markers with similar tolerability. | |||||
書誌情報 |
Osteoporosis International 巻 23, 号 6, p. 1737-1745, 発行日 2011-06-01 |
|||||
出版者 | ||||||
出版者 | Springer-Verlag | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0937941X | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14332965 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s00198-011-1782-z | |||||
権利 | ||||||
権利情報 | © The Author(s) 2011. This article is published with open access at Springerlink.com | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Osteoporosis International, 23(6), pp.1737-1745; 2012 |